Tenax Therapeutics, Inc. · NASDAQ:TENX

Tenax Therapeutics — Technical Presentation (June 2020)

14 slides from Tenax Therapeutics's technical presentation, Jun 2, 2020

  1. Slide 1: HELP Study Topline Results

    HELP Study Topline Results June 2, 2020

  2. Slide 2: HELP Study Phase 2 Objectives

    HELP Study Phase 2 Objectives = HELP Study Objectives 1. Explore hemodynamic markers of effectiveness in PH-HFpEF 2. Explore safety of chronic Levosimendan dosing in PH-HFpEF 3. Explore a potential signal of clinical effectiveness in PH-HFpEF = We have achieved all these objectives in the HELP Study

  3. Slide 3: Pulmonary Hypertension Prevalence and Market Size

    Pulmonary Hypertension Prevalence and Market Size Estimated Prevalence by WHO Group Pharmaceutical Sales >$5 billion in 2016 (primarily in Group 1) oe WHO Group 1 roup 5 3% 3% WHO Group 4 2% Pfizer $285M Bayer $279M Source: Pulmonary Hypertension Assocation Strange G etal. Heart. 2012;98(24:1805-11

  4. Slide 4: HELP Study Design

    HELP Study Design Open-Label Lead-In Chronic Phase Week 6 24 hours 5 weeks Final Evaluation (0.1 e/kg/rain) ;—* Levosimendan n=18 “> Responders _n=36 _| weekly infusion through Week 5 Levosimendan —— enrolled patients . Placebo n=18 ‘——» Non-Responders titration at Week 4, as tolerated (0.075 > 0.1

  5. Slide 5: Baseline Characteristics

    Baseline Characteristics n=18 | n=18 Age, median (range), years 67.5 (43-81) 68.8 (54-80) NS <65% 38.9 27.8 Ns >=65 % 61.1 72.2 Female sex, % 66.7 55.6 NS White race, % 88.9 88.9 NS Ethnicity (not hispanic or latino), % 100 94.4 NS Body Mass Index, median (range), % 32.7 (22-52) 35.6 (23-57) NS Base

  6. Slide 6: PCWP Change from Baseline at Week 6

    PCWP Change from Baseline at Week 6 Levosimendan vs Placebo Rest Legs Up mPlacebo mlLevosimendan mPlacebo mLevosimendan SSS 03 aoytl P= 0.0894 P= 0.0184 Exercise at 25 Watts Primary Endpoint ™Placebo m™Levosimendan SEs -0.5 P= 0.6472

  7. Slide 7: PCWP Endpoint

    PCWP Endpoint Baseline versus 6 Weeks Placebo Levosimendan 50 —» Baseline 50 —e— Baseline —e—6 Weeks —s— 6 Weeks —40 —40 2 2 € 30 £30 E E 2 20 2 20 5 5 240 p=0.6615 + 2 40 =0.0017 + Legs 25 Rest Legs 25 Rest Up Watts Up Watts Lo p=0.0475t ed Levosimendan effect on PCWP across positions significant v

  8. Slide 8: 6 Minute Walk Change from Baseline

    6 Minute Walk Change from Baseline Levosimendan vs Placebo Change in 6 Minute Walk Distance(meters) at Week 6 Levosimendan vs Placebo 16.6 -12.7 mPlacebo mLevosimendan +29 Meters Mean Diff 29.3 SE 13.14 95% Cl (2.5, 56.1) p-value 0.0329

  9. Slide 9: RAP Change from Baseline at Week 6

    RAP Change from Baseline at Week 6 Levosimendan Treated Patients Exercise -3.9, 14% Change from Baseline (mm Hg) ‘ % i ua P= 0.0356 5 P= 0.0004 P=0.005

  10. Slide 10: mPAP Week 6

    mPAP Week 6 Levosimendan Change from Baseline Exercise -2.78, 2% P= 0.1452 Change from Baseline (mmHg)

  11. Slide 11: Treatment Emergent Adverse Events

    Treatment Emergent Adverse Events Placebo Levosimendan n=18 n=18 Any Treatment Emergent AEs (TEAEs) 8 (44%) 13 (72%) TEAEs by Severity Mild 5 (28%) 9 (50%) Moderate 2 (11%) 2 (11%) Severe 1 (6%) 2 (11%) Any Drug-Related TEAEs 5 (28%) 9 (50%) TEAEs of Special Interest t 0 0 Serious TEAEs 1 (6%) 3 (17

  12. Slide 12: Treatment Emergent Adverse Events

    Treatment Emergent Adverse Events (Incidence of 2 or more) | Placebo | Levosimendan | n=18 n=18 Headache 1 (6%) 3 (17%) Heart Rate Increased 0 (0%) 2 (11%) Fatigue 2 (11%) 1 (6%) Cardiac Failure Acute 1 (6%) 2 (11%) Dyspnea 1 (6%) 2 (11%) Vascular Access Site Pain 2 (11%) 0 (0%) Muscle Spasms 0(0%)

  13. Slide 13: Serious Adverse Events

    Serious Adverse Events - : Relatedness/ Event on Levosimendan Severity Change in Dose Infections and Infestations, severe not related, Device related infection dose interrupted Infections and Infestations, i not related, Bacteremia moderate dose not changed Cardiac disorders, mild not related, Cardi

  14. Slide 14: HELP Study Topline Results

    HELP Study Topline Results Support Phase 3 Development in PH-HFpEF 1. Evidence of levosimendan efficacy in PH-HFpEF = Evidence of hemodynamic improvements with biventricular effects(PCWP,RAP, PAP) = Evidence of significant improvement in exercise performance, 6-Minute Walk ® Statistically significan

Tenax Therapeutics — Technical Presentation (June 2020) on 6ix